• Mei-Chi Tsui, Chia-Hsien ChengJasonJDivision of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taiwan., and Chang-Ping Lin.
• Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan; An Nan Hospital, China Medical University, Tainan, Taiwan.
• J Formos Med Assoc. 2023 Nov 1; 122 (11): 111711241117-1124.

PurposeTo investigate the treatment outcome, visual outcome, and adverse effects of five-fraction stereotactic radiosurgery (SRS) to medium- and large-sized uveal melanoma with a non-invasive eye immobilization device.MethodsMedical records of 14 patients with uveal melanoma receiving SRS with a total dose of 50 Gy in five fractions from 2008 to 2017 were retrospectively reviewed. A non-invasive eye fixation device was used to achieve and monitor eye immobilization.ResultsLocal tumor control rates were 85.7% and 75.0% at 2 and 5 years, respectively. The average tumor diameter decreased significantly from 10.0 ± 3.21 mm to 8.36 ± 3.71 mm (p = 0.038) 15 months after SRS, while the average tumor thickness decreased significantly from 5.45 ± 2.21 mm to 4.34 ± 2.29 (p = 0.036) 21 months after SRS. The 5-year metastasis-free survival was 87.5%. The mean best-corrected visual acuity (BCVA) deteriorated from logMAR 0.296 at baseline to logMAR 1.112 at the last individual follow-up visits (p < 0.001). Adverse effects of SRS were comparable to those reported with proton-beam radiotherapy or Gamma knife therapy.ConclusionSRS combined with a non-invasive eye immobilization device is an effective and safe alternative eye-preserving treatment for medium- to large-sized uveal melanoma. BCVA at 3 months may be a predictor for BCVA at 1 year.Copyright © 2023. Published by Elsevier B.V.

16 keywords...

hide…